Licensing status

Publication and contact information

Infectious disease


HIV gp120

Nonhuman primate studies suggest the broadly neutralizing, anti-HIV gp120 mAb PGT121 could be used to treat HIV infection. In rhesus macaques chronically infected with a pathogenic simian-human immunodeficiency virus (SHIV), PGT121 led to transient virological control in four of four macaques and longer-term control in one of four macaques. In the monkeys, PGT121 decreased viral RNA in plasma and proviral DNA in blood and tissues and increased T cell responses and functionality compared with a control antibody. Next steps include testing the mAb in combination with antiretroviral therapies in SHIV-infected rhesus macaques.
The International AIDS Vaccine Initiative (IAVI) and Theraclone Sciences Inc. are collaborating on PGT121 and additional anti-HIV antibodies; IAVI retains rights to develop vaccines based on these findings, whereas Theraclone retains rights to develop therapeutics based on these antibodies.

SciBX 6(46); doi:10.1038/scibx.2013.1324
Published online Dec. 5, 2013

Patent status undisclosed; PGT121 available for partnering and licensing from Theraclone Sciences

Barouch, D.H. et al. Nature; published online Oct. 30, 2013;
Contact: Dan H. Barouch, Beth Israel Deaconess Medical Center and Harvard Medical School,
Boston, Mass.